NBQX Disodium (FG9202 disodium) is a highly selective, competitive AMPA receptor antagonist with neuroprotective and anticonvulsant activity. NBQX Disodium is a salt of NBQX. NBQX is a potent and selective AMPA/rhodosinate receptor antagonist that can be used to antagonize the excitatory toxicity of glutamate. It has anticonvulsant effects in rodent models.

Kainic acid:0.7 ± 0.03 μM, AMPA:0.7 ± 0.1 μM

In HIP-009 cells, NBQX disodium salt inhibited both AMPA or kainic acid (KA) induced signals in a concentration-dependent manner, with IC50 values being 0.7 ± 0.1 and 0.7 ± 0.03 μM, respectively. The AMPA-evoked calcium rise was completely inhibited by NBQX disodium salt, whereas 68.6% ± 1.3% inhibition of the KA-induced signal was observed with 30 μM of NBQX disodium salt treatment.[1]

Administration of NBQX disodium (FG9202; 20 mg/kg, i.p.; for 3 days) exhibits a reduction in PTZ-induced seizures. [2]
In a rat model of focal ischemia, NBQX disodium demonstrates neuroprotective effects when administered intravenously as a bolus dose of 30 mg/kg at the time of MCA occlusion, followed by an additional dose at 1 hour post-occlusion. [3]